Braiteh FS - Search Results

1

Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.

Pant S, Hamilton E, Ulahannan SV, Strauss JF, Braiteh FS, Huang M, Liaw DCH. Pant S, et al. Among authors: braiteh fs. Cancer. 2023 Jun 15;129(12):1919-1929. doi: 10.1002/cncr.34733. Epub 2023 Mar 27. Cancer. 2023. PMID: 36970876 Clinical Trial.

2

Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.

Thomas SP, Jacobson LE, Victorio AR, Operaña TN, Schroeder BE, Schnabel CA, Braiteh F. Thomas SP, et al. JCO Precis Oncol. 2018 Nov;2:1-12. doi: 10.1200/PO.17.00145. JCO Precis Oncol. 2018. PMID: 35135112

3

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. Adjei AA, et al. Clin Cancer Res. 2016 May 15;22(10):2368-76. doi: 10.1158/1078-0432.CCR-15-1681. Epub 2015 Dec 7. Clin Cancer Res. 2016. PMID: 26644411 Free PMC article. Clinical Trial.

4

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Chung V, et al. Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30. Clin Cancer Res. 2017. PMID: 28039265

5

First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.

Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. Garrido-Laguna I, et al. Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23. Int J Cancer. 2019. PMID: 30680712 Free PMC article. Clinical Trial.

6

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Liu JF, et al. Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. Epub 2019 Jun 14. Gynecol Oncol. 2019. PMID: 31204078 Clinical Trial.

7

A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.

Chawla SP, Goel S, Chow W, Braiteh F, Singh AS, Olson JEG, Osada A, Bobe I, Riedel RF. Chawla SP, et al. Clin Cancer Res. 2020 Aug 15;26(16):4225-4232. doi: 10.1158/1078-0432.CCR-20-0591. Epub 2020 May 7. Clin Cancer Res. 2020. PMID: 32381487 Clinical Trial.

8

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.

Tap WD, Singh AS, Anthony SP, Sterba M, Zhang C, Healey JH, Chmielowski B, Cohn AL, Shapiro GI, Keedy VL, Wainberg ZA, Puzanov I, Cote GM, Wagner AJ, Braiteh F, Sherman E, Hsu HH, Peterfy C, Gelhorn HL, Ye X, Severson P, West BL, Lin PS, Tong-Starksen S. Tap WD, et al. Clin Cancer Res. 2022 Jan 15;28(2):298-307. doi: 10.1158/1078-0432.CCR-21-2007. Epub 2021 Oct 29. Clin Cancer Res. 2022. PMID: 34716196 Free PMC article.

9

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.

Li L, Braiteh FS, Kurzrock R. Li L, et al. Among authors: braiteh fs. Cancer. 2005 Sep 15;104(6):1322-31. doi: 10.1002/cncr.21300. Cancer. 2005. PMID: 16092118 Free article.

10

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.

Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Braiteh F, et al. Clin Cancer Res. 2008 Oct 1;14(19):6296-301. doi: 10.1158/1078-0432.CCR-08-1247. Clin Cancer Res. 2008. PMID: 18829512 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page